A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types

This publication has 63 references indexed in Scilit:

• Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
  The Lancet Infectious Diseases, 2012
• Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
  The Lancet Oncology, 2012
• HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection
  Vaccine, 2011
• The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies
  Virology, 2011
• A Recombinant Flagellin-Poxvirus Fusion Protein Vaccine Elicits Complement-Dependent Protection Against Respiratory Challenge with Vaccinia Virus in Mice
  Viral Immunology, 2010
• Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin
  Vaccine, 2009
• Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20–38) peptide displayed on bacterial thioredoxin
  Vaccine, 2009
• Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2
  Proceedings of the National Academy of Sciences, 2008
• Protein production by auto-induction in high-density shaking cultures
  Protein Expression and Purification, 2005
• Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility
  Nature Immunology, 2003